Wen Si, He Fang, Zhu Xuejing, Yuan Shuguang, Liu Hong, Sun Lin
Department of Nephrology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Department of Nephrology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, Guangdong, China.
Clin Exp Rheumatol. 2018 Jan-Feb;36(1):36-43. Epub 2017 Jun 16.
IFN-γ, CXCL16 and uPAR have recently been regarded as potential biomarkers in systemic lupus erythematosus (SLE). However, few researches have focused on the comparison of these three markers in SLE. We conducted this study to evaluate their role as biomarkers of disease activity and renal damage.
We enrolled 50 SLE patients with or without lupus nephritis (LN) and 15 healthy control subjects. The levels of IFN-γ, CXCL16, uPAR in serum, urine and renal tissues were detected by ELISA or immunohistochemistry. Relevant clinical and laboratory features were recorded.
Serum and urine IFN-γ, CXCL16 and suPAR levels in SLE patients were significantly higher than that in healthy controls. Moreover, LN patients had higher levels than non-LN patients. A positive correlation was observed between these markers, and disease activity and suPAR had a stronger association with disease activity. The expression of these biomarkers in renal tissues was significantly higher in LN patients and was also associated with the activity of pathological lesions.
IFN-γ, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in SLE.
干扰素-γ（IFN-γ）、CXC趋化因子配体16（CXCL16）和尿激酶型纤溶酶原激活物受体（uPAR）最近被视为系统性红斑狼疮（SLE）的潜在生物标志物。然而，很少有研究关注这三种标志物在SLE中的比较。我们开展这项研究以评估它们作为疾病活动和肾损伤生物标志物的作用。
我们纳入了50例有或无狼疮性肾炎（LN）的SLE患者以及15名健康对照者。采用酶联免疫吸附测定（ELISA）或免疫组化法检测血清、尿液和肾组织中IFN-γ、CXCL16、uPAR的水平。记录相关临床和实验室特征。
SLE患者血清和尿液中的IFN-γ、CXCL16和可溶性尿激酶型纤溶酶原激活物受体（suPAR）水平显著高于健康对照者。此外，LN患者的这些水平高于非LN患者。这些标志物之间观察到正相关，且疾病活动与suPAR和疾病活动的关联更强。这些生物标志物在肾组织中的表达在LN患者中显著更高，并且也与病理病变的活动相关。
IFN-γ、CXCL16和uPAR有望作为SLE疾病活动、肾损伤及病理病变活动的有效生物标志物。
